MIRA
NASDAQMIRA Pharmaceuticals Inc.
News25/Ratings0
News · 26 weeks33-100%
2026-04-192026-10-11
Mix1090d
- SEC Filings7(70%)
- Other3(30%)
Latest news
25 items- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- PRMIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has been submitted for Institutional Review Board (IRB) review at a leading cancer research institution. MIRA incorporated the FDA's feedback into the protocol and is targeting site initiation in the first quarter of 2027, subject to completion of IRB review and other routine site activation requi
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECSEC Form 10-Q filed by MIRA Pharmaceuticals Inc.10-Q - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- PRMIRA Reports Positive 7-Day Dog Study Results for SKNY-1Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development. The study evaluated SKNY-1 following repeated d
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- PRMIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling StudiesMIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced continued advancement of its two lead preclinical programs, MIRA-55, an investigational oral non-opioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders. Over the past several weeks, the Company has advanced both programs through multiple coordinated development activities, including formulation optimization, chemistry, manufacturing and controls (CMC) activities, manufacturing developm
- SECSEC Form DEF 14A filed by MIRA Pharmaceuticals Inc.DEF 14A - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory PainOptimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company's oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain.Following evaluation of multiple oral formulations, the Company selected a lead formulation demonstrating favorable oral bioavailability together with sustained systemic exposure an
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and AddictionNew Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential MIAMI, FL / ACCESS Newswire / July 6, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company's oral drug candidate being developed for obesity and addiction-related disorders.The studies demonstrated favorable oral bioavailability together with reproducible systemic exposure and robust brain penetration, and substantial liver exposure following oral administration. Peak p
- NEWSMIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THCData show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism, while demonstrating anxiolytic activity, which THC does not produce, supporting continued development for chronic inflammatory pain MIAMI, FL / ACCESS Newswire / June 25, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical pharmacology data on Mira-55, the Company's cannabinoid analog in development for chronic inflammatory pain. Mira-55 is designed to act on the same can
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- NEWSMIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral NeuropathyRandomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center MIAMI, FL / ACCESS Newswire / June 17, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2, the Company's proprietary oral NMDA receptor modulator, in chemotherapy-induced peripheral neuropathy (CIPN).Addressing a Significant Unmet Medical NeedChemotherapy
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- INSIDERSEC Form 4 filed by Director Shekhat Denil Nanji4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mushak Andriy3 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
- SECMIRA Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
MIRA FAQ
5 questionsWhere does MIRA stock trade?
MIRA Pharmaceuticals Inc. (MIRA) is listed on NASDAQ.What sector and industry is MIRA in?
MIRA Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MIRA Pharmaceuticals Inc. go public?
MIRA Pharmaceuticals Inc. (MIRA) completed its IPO in 2023.What companies are similar to MIRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MIRA side-by-side with any of them on Quantisnow.How can I track MIRA on Quantisnow?
Quantisnow aggregates MIRA Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRA to receive live email and push alerts on every new disclosure.